Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

This study has been terminated.
(Closed due to insufficient recruitment.)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00234442
First received: October 5, 2005
Last updated: June 29, 2009
Last verified: June 2009

October 5, 2005
June 29, 2009
July 2004
Not Provided
Disease control rate (complete response, partial response and stable disease)
Same as current
Complete list of historical versions of study NCT00234442 on ClinicalTrials.gov Archive Site
  • Duration of response
  • Time to progression
  • Overall Survival
Same as current
Not Provided
Not Provided
 
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Brain Neoplasms
  • Non Small Cell Lung Cancer
Drug: Iressa (Gefitinib)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
47
February 2006
Not Provided

Inclusion Criteria:

  • Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
  • No symptoms due to brain metastases
  • No previous radiotherapy treatment for the Brain metastases

Exclusion Criteria:

  • No prior chemotherapy
  • No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00234442
1839IL/0569
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Lucio Crino, MD Bologna, Italy
AstraZeneca
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP